This is 10 year old male child with complain of feeling of short size penis. What should be next step and what about report
micropenis hypogonadotropic hypogonadism child management
10 year old child low FSH LH testosterone hypogonadotropic hypogonadism evaluation next steps 2024
| Test | Result | Reference Range | Interpretation |
|---|---|---|---|
| FSH | 0.848 mIU/mL | Males: 1.5–11.8 mIU/mL | ⬇️ LOW |
| LH | 0.113 mIU/mL | Males: 1.1–25 mIU/mL | ⬇️ LOW |
| Total Testosterone | 1.04 ng/mL | Boys 1–18 yrs: <10.03 ng/mL | ✅ Within age range (prepubertal) |
| Test | Reason |
|---|---|
| Bone age X-ray (left hand) | Differentiates CDGP (delayed bone age) from true HH |
| Prolactin | Rule out prolactinoma causing HH |
| IGF-1 & IGFBP-3 | Rule out concomitant GH deficiency |
| Thyroid function (TSH, FT4) | Hypothyroidism can mimic delayed puberty |
| Karyotype | If primary HH suspected; also screens for Klinefelter (47XXY) |
| GnRH stimulation test | If available: inject GnRH, measure LH/FSH at 30/60 min — distinguishes CDGP from true HH (blunted response = HH) |
| hCG stimulation test | Inject hCG, check testosterone at 72h — tests Leydig cell reserve |
| Diagnosis | Clue |
|---|---|
| Constitutional delay (CDGP) | Family history, delayed bone age, normal MRI, LH normalizes later |
| Kallmann syndrome | Anosmia, absent olfactory bulbs on MRI, low LH/FSH |
| Idiopathic HH (normosmic) | Same as Kallmann but normal smell |
| Pituitary/hypothalamic tumor | Headache, visual changes, abnormal MRI |
| Buried penis | Obese child, normal hormones, penis retracted in fat |
| Prader-Willi syndrome | Hypotonia history, obesity, short stature, FTT as infant |
This 10-year-old's hormonal profile shows suppressed gonadotropins (FSH 0.848, LH 0.113) — both significantly below the normal range. This is not simply a prepubertal baseline but an abnormally low pattern that warrants urgent further evaluation. The combination with a perceived small penis size makes hypogonadotropic hypogonadism the primary concern until proven otherwise.
— Harrison's Principles of Internal Medicine 22E (2025): "Those with the most severe congenital gonadotropin deficiency have complete absence of pubertal development, and in some cases, hypospadias, undescended tests, and micropenis." Low LH/FSH with micropenis in a prepubertal child necessitates a structured evaluation as outlined above.
Medical treatment for low grade varicocele in young male
varicocele medical treatment young male fertility
low grade varicocele grade 1 medical treatment conservative management young male 2024
varicocele conservative management antioxidant therapy sperm parameters
varicocele grade 1 observation vs surgery adolescent
varicocele watchful waiting antioxidants vitamin E folate sperm DNA fragmentation
| Grade | Clinical Finding |
|---|---|
| Grade 1 (Low) | Palpable only during Valsalva maneuver |
| Grade 2 | Palpable at rest without Valsalva |
| Grade 3 | Visible through scrotal skin |
| Subclinical | Detected only on Doppler/imaging, not palpable |
"Observation remains the approach of choice for the majority of adolescents with varicocele until a surgical indication is present." — Campbell-Walsh-Wein Urology
| Agent | Dose | Evidence |
|---|---|---|
| Vitamin E (α-tocopherol) | 400 IU/day | Cochrane review: may improve live birth rates in ART |
| Vitamin C | 1000 mg/day | Synergistic with Vit E; reduces oxidative DNA damage |
| Zinc | 66 mg/day | Improved sperm density and motility in small RCTs |
| Coenzyme Q10 (Ubiquinone) | 200–300 mg/day | Improved sperm density and motility vs. placebo in multiple controlled trials |
| Folic acid | 5 mg/day | Often combined with zinc; reduces sperm DNA aneuploidy |
| Selenium | 100–200 mcg/day | Cofactor for antioxidant enzymes (glutathione peroxidase) |
| L-Carnitine / Acetyl-L-Carnitine | 2–3 g/day | Improves sperm motility; mitochondrial energy substrate |
Note: Campbell-Walsh-Wein (2024): "Antioxidant supplementation in subfertile men may increase live birth rates, especially for Vitamin E, zinc, and multivitamin." Larger blinded RCTs are still awaited before definitive recommendations.
| Interval | Assessment |
|---|---|
| Every 6–12 months | Clinical exam, testicular volume (Prader orchidometer or US) |
| Annual ultrasound | Monitor for testicular atrophy/asymmetry |
| Semen analysis | At Tanner stage 5 / ≥18 years of age (earlier if concerns) |
| Hormones (FSH, LH, Testosterone) | If growth arrest or semen abnormality detected |
Grade 1 Varicocele in Young Male
│
▼
Normal testicular volume + no pain + prepubertal/early pubertal?
│
YES → WATCHFUL WAITING
+ Antioxidants (Vit E, C, Zinc, CoQ10)
+ Lifestyle modification
+ 6–12 monthly follow-up
│
NO (atrophy/pain/abnormal semen)
▼
Surgical referral (varicocelectomy)
— Campbell-Walsh-Wein Urology; Smith & Tanagho's General Urology 19e
Tell me pharmacological treatment for perisistant pain
varicocele persistent scrotal pain pharmacological treatment NSAIDs neuropathic analgesics 2024
chronic scrotal pain varicocele pharmacological treatment
| Drug Class | Examples | Dose | Rationale |
|---|---|---|---|
| NSAIDs | Ibuprofen | 400–600 mg TID with food | Analgesic + anti-inflammatory; first choice for acute-on-chronic flares |
| Naproxen | 250–500 mg BD | Longer-acting; good for persistent dull aching pain | |
| Diclofenac | 50 mg BD–TID | Good tissue penetration; often used in scrotal/pelvic pain | |
| Paracetamol | Acetaminophen | 500–1000 mg TID–QID | Adjunct or monotherapy if NSAIDs contraindicated |
| COX-2 inhibitors | Celecoxib | 200 mg OD–BD | Preferred if GI risk; similar analgesic efficacy |
Note: Evidence for a specific NSAID target in varicocele pain is limited — these work via general analgesia. Use for 4–6 weeks; reassess.
| Drug | Dose | Duration | Why |
|---|---|---|---|
| Doxycycline | 100 mg BD | 2–4 weeks | Excellent scrotal tissue penetration; covers Chlamydia, atypicals |
| Fluoroquinolones (Ciprofloxacin / Levofloxacin) | Cipro 500 mg BD or Levo 500 mg OD | 2–4 weeks | Broad coverage; good penetration into testis/epididymis |
Campbell-Walsh-Wein: "Antibiotics are commonly used but rarely indicated [in CSPS]. Doxycycline and quinolones are recommended because of their penetration into scrotal structures."
| Drug | Class | Dose | Notes |
|---|---|---|---|
| Amitriptyline | Tricyclic antidepressant (TCA) | 10–25 mg at night, titrate to 50–75 mg | Gold standard for neuropathic pain; also improves sleep |
| Nortriptyline | TCA (less sedating) | 10–25 mg nocte | Better tolerated than amitriptyline; less anticholinergic |
| Gabapentin | Anticonvulsant / neuropathic | 300 mg TID → titrate to 900–1800 mg/day | Reduces central sensitization; evidence in orchialgia |
| Pregabalin | Alpha-2-delta ligand | 75 mg BD → 150 mg BD | Faster onset than gabapentin; licensed for neuropathic pain |
Campbell-Walsh-Wein: "Given that CSPS is a chronic pain condition, medications used for neuropathic pain are prescribed. These include tricyclic antidepressants and gabapentin."
| Drug | Dose | Indication |
|---|---|---|
| Tramadol | 50–100 mg TID (max 400 mg/day) | Moderate–severe pain unresponsive to NSAIDs; short-term use |
| Duloxetine (SNRI) | 30–60 mg OD | Chronic pain + mood component; neuropathic pain |
| Venlafaxine | 75 mg OD | Alternative SNRI; evidence in pelvic pain syndromes |
| Cyclobenzaprine | 5–10 mg TID | If pelvic floor muscle spasm contributing |
| Intervention | Details |
|---|---|
| Spermatic cord block | 0.5% bupivacaine injection near external inguinal ring — diagnostic + therapeutic; >50% pain relief predicts response to surgical denervation |
| Botulinum toxin A | 100 units into spermatic cord — 72% pain reduction at 1 month; effect temporary (~6 months) |
| Pulsed radiofrequency | Applied to spermatic cord; mean VAS pain decreased from 9→1 |
| Sacral neuromodulation | For refractory cases; targets S2–S4 |
Persistent varicocele pain
│
▼
Step 1: NSAIDs (4–6 weeks) + scrotal support
│ Fails
▼
Step 2: Antibiotic trial (Doxycycline 4 weeks)
│ Fails
▼
Step 3: Neuropathic agents — Amitriptyline 25–50 mg nocte
OR Gabapentin 300–900 mg TID (8–12 weeks)
│ Fails
▼
Step 4: Spermatic cord block (diagnostic + therapeutic)
│ Positive response
▼
Step 5: Surgical — MSCD or varicocelectomy
— Campbell-Walsh-Wein Urology (3-Volume Set)
What are the components of standard flush therapy for small ureteric stone with mild hydronephrosis in a young male
ureteral stone medical expulsive therapy alpha blocker
PMID: 39875883
| Drug | Dose | Notes |
|---|---|---|
| Silodosin (α1a-selective) | 8 mg OD | More selective for ureter; evidence shows superiority to tamsulosin for large distal ureteral stones |
| Nifedipine (CCB) | 30 mg XL OD | Second-line; inferior to tamsulosin in head-to-head trials; relaxes ureteral smooth muscle via calcium blockade |
| Tadalafil (PDE-5 inhibitor) | 10 mg OD x 10–14 days | Emerging evidence; PDE-5 inhibitors reduce ureteral tone; combination with α-blocker superior to α-blocker alone (2025 NMA, PMID 39875883) |
| Drug | Dose | Route |
|---|---|---|
| Ibuprofen | 400–600 mg TID–QID | Oral (with food) |
| Diclofenac | 50 mg BD–TID | Oral/IM |
| Ketorolac | 15–30 mg | IV/IM (if vomiting) |
| Naproxen | 250–500 mg BD | Oral |
| Component | Drug | Dose | Duration |
|---|---|---|---|
| Alpha blocker (MET) | Tamsulosin | 0.4 mg OD (night) | 4–6 weeks |
| Hydration | Water/oral fluids | 2–3 L/day | Continuous |
| NSAID | Ibuprofen/Diclofenac | 400–600 mg TID | As needed |
| Corticosteroid | Deflazacort | 30 mg OD | 5–10 days |
| Antispasmodic | Hyoscine butylbromide | 10–20 mg TID | During colic |
| Antiemetic | Ondansetron | 4–8 mg TID PRN | As needed |
| Interval | Assessment |
|---|---|
| Every 1–2 weeks | Repeat ultrasound — check hydronephrosis progression |
| Ongoing | Pain diary, urine straining (to confirm stone passage) |
| If no passage at 4 weeks | Repeat imaging (NCCT); consider urological intervention |
— Goldman-Cecil Medicine; Brenner & Rector's The Kidney 2-Volume Set; Campbell-Walsh-Wein Urology; network meta-analysis Taheri et al., BMC Urol 2025 [PMID 39875883]
What should be removed first in Laparascopic pyeloplasty, abdominal drain kept near pelviureteric anastomosis or per urethral catheter?
laparoscopic pyeloplasty drain removal urethral catheter postoperative protocol
| Step | Timing | What is Removed |
|---|---|---|
| Step 1 | Post-op Day 1–2 (24–36 hours) | Foley catheter removed first |
| Step 2 | Before hospital discharge (typically day 2–3), once drain output is negligible | Abdominal drain removed second |
| Step 3 | 4–6 weeks later (outpatient) | Ureteral JJ stent removed |
Campbell-Walsh-Wein Urology: "The Foley catheter is usually removed 24 to 36 hours postoperatively, and the surgical drain is removed before hospital discharge if the drain output remains negligible."
Campbell-Walsh-Wein: "If the drain output increases after the Foley catheter removal, the Foley catheter should be replaced for 7 days to eliminate urinary reflux along the stent in the treated ureter and decrease urinary extravasation at the ureteropelvic anastomosis."
Post-op Day 1–2
↓
Remove FOLEY CATHETER first
↓
Monitor drain output for 12–24 hours
↓
Drain output low/nil? Drain output increases?
↓ ↓
Remove DRAIN Reinsert Foley x 7 days
(before discharge) → then reassess drain
↓
4–6 weeks later:
Remove JJ URETERAL STENT (outpatient)
— Campbell-Walsh-Wein Urology, 3-Volume Set (Postoperative Care and Complications, Laparoscopic Pyeloplasty section)
Is RL in post op period(post ureteric stone surgery)contraindicated in a patient of 80 yrs, female, Hupertensive controlled with s. Creatinine of 1.37 mg/dl?
Ringer lactate balanced crystalloid renal impairment postoperative outcomes
balanced crystalloid versus normal saline acute kidney injury hyperkalemia
Ringer lactate normal saline renal insufficiency hyperkalemia perioperative
balanced crystalloid saline SMART SALT-ED trial kidney outcomes
| Parameter | Value |
|---|---|
| S. Creatinine | 1.37 mg/dL |
| Age | 80 years |
| Sex | Female |
| Estimated GFR (CKD-EPI) | ~30–35 mL/min/1.73m² (CKD Stage 3b) |
In an 80-year-old woman with low muscle mass, a creatinine of 1.37 mg/dL corresponds to moderately reduced GFR (~CKD 3b), not "near-normal" as it might in a young male. This is a crucial clinical distinction.
| Component | RL Content |
|---|---|
| Sodium | 130 mEq/L |
| Potassium | 4 mEq/L |
| Calcium | 2.7 mEq/L |
| Chloride | 109 mEq/L |
| Lactate | 28 mEq/L |
| pH | 6.5 |
| Osmolality | 273 mOsm/L |
| Condition | RL Status |
|---|---|
| End-stage renal disease (oliguria/anuria) | ❌ Contraindicated — risk of hyperkalemia |
| Pre-existing hyperkalemia (K⁺ >5.5 mEq/L) | ❌ Contraindicated |
| Severe acidosis with K⁺ shift | ⚠️ Use with caution |
| Moderate CKD (GFR 30–60) with normal K⁺ | ✅ Can be used cautiously |
| Mild CKD, controlled, normal K⁺ | ✅ Generally safe |
Miller's Anesthesia 10e: Concerns about D-lactate toxicity in renal failure "have not been confirmed in human studies at plasma levels achievable with racemic lactated Ringer solution. The metabolism of D-lactate appears to be nearly as rapid as that of L-lactate."
| Fluid | Risk |
|---|---|
| 0.9% Normal Saline | High chloride (154 mEq/L) → hyperchloremic metabolic acidosis → worsens renal perfusion → higher risk of AKI and need for RRT |
| RL (Balanced crystalloid) | Lower chloride (109 mEq/L) → preserves acid-base balance → BETTER renal outcomes in critically ill patients |
Counter-intuitively, RL is actually MORE kidney-friendly than normal saline in most post-op scenarios, including mild-moderate CKD.
| Factor | Risk | Mitigation |
|---|---|---|
| CKD 3b (GFR ~30–35) | Reduced K⁺ excretion — risk of hyperkalemia with large volumes | Check pre-op K⁺; use with monitoring; limit volume |
| Age 80 | Reduced cardiac reserve, impaired urine concentrating ability | Goal-directed fluid therapy; avoid fluid overload |
| Hypertension (controlled) | Sodium load may worsen BP; may be on ACE inhibitor/ARB (K⁺ retaining) | Check antihypertensive drugs; monitor BP |
| Post ureteric stone surgery | Usually short procedure; moderate fluid requirement | Modest volumes (1–1.5L) typically sufficient post-op |
| Lactate metabolism | At GFR 30–35, lactate clearance slightly impaired | Not clinically significant unless hepatic failure co-exists |
In this 80-year-old controlled hypertensive female with S. Creatinine 1.37 mg/dL (estimated GFR ~30–35 mL/min), RL is NOT absolutely contraindicated — but she has moderate CKD and the potassium in RL requires vigilance. Check K⁺ first. If normal, use RL cautiously at restricted volumes with monitoring. Paradoxically, RL is safer than 0.9% Normal Saline in CKD because it avoids hyperchloremic acidosis and has better renal outcome data.
— Miller's Anesthesia 10e (Balanced Crystalloid Solutions)
Oncobcg schedule for ca bladder pt post turbt
BCG intravesical therapy non-muscle invasive bladder cancer schedule maintenance
| Condition | Timing |
|---|---|
| Earliest start | 2–4 weeks after TURBT (allows mucosal healing) |
| Must NOT start if | Gross haematuria present, traumatic catheterization, active UTI, recent TURBT within 2 weeks |
| Do NOT give | Immediately post-TURBT (unlike mitomycin C which is given within 6 hours) |
Important: A single immediate post-TURBT instillation of Mitomycin C 40 mg is standard of care FIRST (given within 6 hours of TURBT to prevent tumour cell reimplantation) — BCG comes later.
| Risk Group | Features | BCG Indication |
|---|---|---|
| Low risk | Single, Ta, G1 (low grade), <3cm, no CIS | BCG NOT indicated (observe or single MMC) |
| Intermediate risk | Multifocal/recurrent Ta-T1 G1-G2, no CIS | BCG ± (MMC alternative) |
| High risk | T1 G3 (high grade), CIS, multifocal T1, recurrent high grade | BCG mandatory |
| Week | Treatment |
|---|---|
| Week 1 | BCG instillation #1 |
| Week 2 | BCG instillation #2 |
| Week 3 | BCG instillation #3 |
| Week 4 | BCG instillation #4 |
| Week 5 | BCG instillation #5 |
| Week 6 | BCG instillation #6 |
| Week 7–12 | Rest (no BCG) → Cystoscopy at 3 months |
| Timepoint | Schedule | Instillations |
|---|---|---|
| Month 3 | 3 weekly instillations | #7, #8, #9 |
| Month 6 | 3 weekly instillations | #10, #11, #12 |
| Month 12 | 3 weekly instillations | #13, #14, #15 |
| Month 18 | 3 weekly instillations | #16, #17, #18 |
| Month 24 | 3 weekly instillations | #19, #20, #21 |
| Month 30 | 3 weekly instillations | #22, #23, #24 |
| Month 36 | 3 weekly instillations | #25, #26, #27 |
Bailey & Love's Surgery 28e: "The treatment is given weekly for 6 weeks, followed by a 3-weekly treatment every 6 months for 3 years."
Smith & Tanagho's General Urology 19e: "The most commonly recommended induction regimen for BCG is weekly for 6 weeks followed by a period of 6 weeks where no BCG is given. Maintenance therapy has shown proven benefit."
TURBT
↓
Within 6 hrs: Single MMC 40mg instillation
↓
2–4 weeks later: BCG Induction begins
↓
Weeks 1–6: BCG once weekly × 6 (Induction)
↓
Week 12 (3 months): Cystoscopy
↓
If clear: Maintenance begins
↓
Month 3, 6, 12, 18, 24, 30, 36:
→ 3 weekly BCG instillations at each visit
↓
Cystoscopy every 3 months for 2 years,
then every 6 months thereafter
| Absolute | Relative |
|---|---|
| Active TB | Immunosuppression (steroids, post-transplant) |
| Gross haematuria / traumatic catheterization | HIV infection |
| Active UTI | Recent BCG sepsis |
| Within 2 weeks of TURBT | Pregnancy |
| Congenital immunodeficiency |
| Side Effect | Frequency | Management |
|---|---|---|
| Dysuria, frequency, urgency | Very common (50–90%) | Symptom management, NSAIDs |
| Low-grade fever (<38.5°C, <48h) | Common | Paracetamol; continue BCG |
| High fever (>38.5°C, >48h) | Uncommon | Stop BCG; Isoniazid 300 mg/day × 3 months |
| Granulomatous prostatitis | ~5% | Isoniazid + Rifampicin |
| BCG sepsis (systemic) | Rare (<1%) | Isoniazid + Rifampicin + Ethambutol ± Cycloserine + Prednisolone 40 mg/day |
| BCG cystitis (contracted bladder) | Rare | May require cystectomy |
Key rule: Do NOT give quinolones (ciprofloxacin/ofloxacin) as prophylaxis as they kill BCG organisms. Use trimethoprim or nitrofurantoin if needed.
— Smith & Tanagho's General Urology 19e; Bailey & Love's Surgery 28e; Lamm DL et al., SWOG Protocol
Oncobcg schedule for ca bladder pt post turbt
| Week | Instillation |
|---|---|
| Week 1 | BCG #1 |
| Week 2 | BCG #2 |
| Week 3 | BCG #3 |
| Week 4 | BCG #4 |
| Week 5 | BCG #5 |
| Week 6 | BCG #6 |
| Weeks 7–12 | Rest → Cystoscopy at 3 months |
| Timepoint | Instillations |
|---|---|
| Month 3 | 3 weekly × 1 |
| Month 6 | 3 weekly × 1 |
| Month 12 | 3 weekly × 1 |
| Month 18 | 3 weekly × 1 |
| Month 24 | 3 weekly × 1 |
| Month 30 | 3 weekly × 1 |
| Month 36 | 3 weekly × 1 |
— Smith & Tanagho's General Urology 19e; Bailey & Love's Surgery 28e; SWOG Lamm Protocol